A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Kim, D-W. [1 ,2 ]
Lee, S-H. [3 ]
Jang, I-J. [4 ]
Park, K-J. [5 ]
Lee, D. H. [6 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
[4] Seoul Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[5] CKD Chong Kun Dang Res Inst Hyojong, Bio Drug Discovery, Yongin, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
998P
引用
收藏
页码：S1010 / S1010
页数：1
相关论文
共 50 条
  • [1] JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results
    Cho, B. C.
    Lee, J-S.
    Han, J-Y.
    Cho, E. K.
    Haura, E.
    Lee, K. H.
    Bauml, J.
    Sanborn, R. E.
    Curtis, M.
    Attiyeh, E.
    Haddish-Berhane, N.
    Bae, K.
    Knoblauch, R.
    Sherman, L.
    Lorenzi, M. V.
    Park, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
    Haura, Eric B.
    Cho, Byoung Chul
    Lee, Jong Seok
    Han, Ji-Youn
    Lee, Ki Hyeong
    Sanborn, Rachel E.
    Govindan, Ramaswamy
    Cho, Eun Kyung
    Kim, Sang-We
    Reckamp, Karen L.
    Sabari, Joshua K.
    Thayu, Meena
    Bae, Kyounghwa
    Knoblauch, Roland Elmar
    Curtin, Joshua
    Haddish-Berhane, Nahor
    Sherman, Laurie Jill
    Lorenzi, Matthew V.
    Park, Keunchil
    Bauml, Joshua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Park, K.
    Ahn, M.
    Lee, S.
    Kim, H. R.
    Hong, M. H.
    Millington, D.
    Curtis, M.
    Triantos, S.
    Chaplan, S.
    Haddish-Berhane, N.
    Knoblauch, R.
    Aguilar, Z.
    Laquerre, S.
    Lorenzi, M.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S344 - S345
  • [4] EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results
    Qing, Z.
    Gabrail, N.
    Uprety, D.
    Rotow, J.
    Han, B.
    Janne, P. A.
    Nagasaka, M.
    Zheng, M.
    Zhang, Y.
    Yang, G.
    Sun, Y.
    Peng, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2022, 33 : S39 - S40
  • [5] Fc-mediated mechanism of action for the novel EGFR-cMET bispecific antibody (JNJ-61186372) in non-small cell lung cancer
    Vijayaraghavan, Smruthi
    Bushey, Barbara
    Lipfert, Lorriane
    Nanjunda, Rupesh
    Lacy, Eilyn R.
    Buckley, Peter
    Laquerre, Sylvie
    Lorenzi, Matthew V.
    Moores, Sheri
    CANCER RESEARCH, 2019, 79 (13)
  • [6] AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond
    Comer, Frank
    Mazor, Yariv
    Hurt, Elaine
    Yang, Chunning
    Fleming, Ryan
    Shandilya, Harini
    Vijayakrishnan, Balakumar
    Sterba, Meghan
    Chen, Ruoyan
    Rosfjord, Edward
    Floch, Nicolas
    Rosenbaum, Anton I.
    Huang, Yue
    Yuan, Jiaqi
    Beaumont, Kevin
    Godfrey, Lisa
    McGrath, Lara
    Arnaldez, Fernanda
    Sapra, Puja
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Development of cMET/cMET/EGFR Trispecific antibody as therapeutic modality for Non-small Cell Lung Cancer.
    Zaman, Mohd
    Huang, Cai
    Kankanamalage, Sachith Gallolu
    Chaudhary, Amit K.
    Dong, Jianbo
    Liu, Yue
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC)
    Duan, Jianchun
    Wang, Jie
    Wang, Zhijie
    Lin, Lin
    Li, Junling
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] ACTIVITY OF PATUPILONE IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Zatloukal, P.
    Mellemgaard, A.
    Sanchez, J. M.
    Perry, M. C.
    Hamm, J. T.
    Van Meerbeeck, J.
    DeLeo, J. J.
    Gao, B.
    Johri, A. R.
    Felip, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 109
  • [10] Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
    Wang, Jie
    Zhong, Jia
    Wu, Lin
    Chen, Bolin
    Wang, Zhe-Hai
    Yao, Yu
    Dong, Xiaorong
    Li, Wei
    Ren, Xiubao
    Hou, Xiaoming
    Zang, Ai-min
    Qu, Xiujuan
    Zhang, Guojun
    Wang, Yongsheng
    Bai, Yuansong
    Liu, Linlin
    Yu, Guohua
    Chen, Xingwu
    Ding, Lieming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345